Covid-19 roundup: EU be­gins re­view­ing Mod­er­na vac­cine; Cure­Vac and EU agree to 405M-dose deal

A day af­ter an­nounc­ing their vac­cine is high­ly ef­fec­tive at pre­vent­ing Covid-19, Mod­er­na said Eu­ro­pean reg­u­la­tors have be­gun a rolling re­view of the prod­uct for ap­proval.

The news sets Mod­er­na’s mR­NA-1273 vac­cine to be one of the first Covid-19 vac­cines au­tho­rized on both sides of the At­lantic, with CEO Stéphane Ban­cel an­tic­i­pat­ing in an in­ter­view Sun­day that the FDA will OK both their vac­cine and the vac­cine co-de­vel­oped by Pfiz­er and BioN­Tech in ear­ly or mid-De­cem­ber. Nei­ther com­pa­ny has yet sub­mit­ted to the US agency.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.